Updated clinical classification of pulmonary hypertension.
By G. Simonneau, M. A. Gatzoulis, Ian Adatia, D. Celermajer, C. Denton, A. Ghofrani, M. Sánchez, R. Kumar, M. Landzberg, R. Machado and 3 more. Journal of the American College of Cardiology, 2009
3,966 citations recorded by the source corpus.
In 1998, a clinical classification of pulmonary hypertension (PH) was established, categorizing PH into groups which share similar pathological and hemodynamic characteristics and therapeutic approaches. During the 5th World Symposium held in Nice, France, in 2013, the consensus was reached to maintain the general scheme of previous clinical classifications. However, modifications and updates especially for Group 1 patients (pulmonary arterial hypertension [PAH]) were proposed. The main change was to withdraw persistent pulmonary hypertension of the newborn (PPHN) from Group 1 because this entity carries more differences than similarities with other PAH subgroups. In the current classification, PPHN is now designated number 1. Pulmonary hypertension associated with chronic hemolytic anemia has been moved from Group 1 PAH to Group 5, unclear/multifactorial mechanism. In addition, it was decided to add specific items related to pediatric pulmonary hypertension in order to create a comprehensive, common classification for both adults and children. Therefore, congenital or acquired left-heart inflow/outflow obstructive lesions and congenital cardiomyopathies have been added to Group 2, and segmental pulmonary hypertension has been added to Group 5. Last, there were no changes for Groups 2, 3, and 4.
Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/522b2ad72b790cc064a405dfe4a62bfd4ad1ceb7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. (2013, background): “Persistent worsening of WHO functional class due to pulmonary hypertension 1 (1) 0”
- Universal Definition and Classification of Heart Failure. (2021, background): “The presence of right HF in the setting of left HF is typically due to postcapillary, World Health Organization group 2 pulmonary hypertension and may require modified treatment approaches and portends a poor prognosis; therefore, recognition of biventricular HF is important.(84) Given the importanc”
- Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society (2015, background): “Indeed, most studies of potential PAH therapeutics have focused on adults and, because of the nature of adult PAH, have generally been conducted in patients with a limited range of associated conditions.2 Thus, pediatric PH has been understudied, and little is understood about the natural history, f”
- Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study (2013, background): “Additional diagnostic criteria may include a normal or reduced cardiac output(1) or a pulmonary vascular resistance (PVR) of >3 Wood units.(2) PAH includes diverse clinical phenotypes, prominent among which is systemic sclerosis (SSc, scleroderma) where PAH has emerged as a leading cause of death.”
- Pulmonary arterial hypertension (2013, methodology): “artery wedge pressure (PCWP) of <15 mmHg [1,2].”
- Molecular pathogenesis of pulmonary arterial hypertension. (2008, background): “Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.”
- Mechanisms of disease: pulmonary arterial hypertension (2011, background): “1 According to the current classification of pulmo nary hypertension, which was agreed upon at the 4 th World Symposium on Pulmonary Hypertension in 2008, five categories of chronic pulmonary hypertension exist (Box 1).”
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial (2016, methodology): “Right heart catheterization is recommended by the WHO to confirm moderate to severe precapillary PH and establish a diagnosis of pulmonary arterial hypertension (PAH).(24) However, only one dasatinib-treated patient with PH had this procedure performed, and it did not support a diagnosis of PAH.”